All News

This newest approval established Ozempic as the most broadly indicted GLP-1 RA in its class.

Metabolic surgery reduced major adverse liver outcomes in people with compensated cirrhosis and obesity by 72%, according to new data.

The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.

Your daily dose of the clinical news you may have missed.

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Cardiovascular disease is still the leading cause of death in the US, driven by rising rates of obesity, diabetes, and hypertension, according to new report.

In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

Your daily dose of the clinical news you may have missed.

Once every four weeks maintenance dosing of lecanemab may be easier for patients and care partners to continue treatment.

Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.

ASCO GI Cancers Symposium: The Freenome blood-based test identified nearly 80% of individuals who had colorectal cancer.

When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.

Weekly subcutaneous injections of amycretin featured a safety profile similar to other incretin-based drugs, according to new topline results.

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.